Previous 10 | Next 10 |
2024-06-05 07:45:00 ET A few years ago, in the race to launch a COVID-19 vaccine, Pfizer (NYSE: PFE) stock was a hot buy after the company ended up with a highly successful product in Comirnaty. The uncertainty surrounding COVID and the potential for there to be a need for ongoing a...
2024-06-05 05:10:00 ET Summary High vacancies, increasing taxes and utilities and heavy debt loads are causing some property owners to simply walk away from significant buildings. Pfizer rose to $61 in December 2020 shortly after its vaccine came to market; it now looks decidedly ...
2024-06-04 16:02:02 ET More on Markets Goldman Sachs: Core inflation will cool to 2.2% in developed economies Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) The Reversal Of The Reversal S&P 500 Investor Focus Shif...
2024-06-04 14:03:15 ET Read the full article on Seeking Alpha For further details see: Pfizer data for breast cancer therapy sends Olema higher
2024-06-04 05:29:00 ET Pfizer (NYSE: PFE) investors have been through a lot of ups and downs over the past few years. If you've been on the sidelines, now could be a great time to buy the stock. Shares of Pfizer have been beaten severely in response to sinking sales of Comirnaty...
2024-06-04 04:20:17 ET Summary Cerevel Therapeutics agreed to be acquired by AbbVie on 12/06/23 for $45/s or ~$8.7B. CERE stock closed on Friday, May 31st at $40.74/s. This presents investors with a potential arbitrage play of over 10% on a deal that should close within the next 3...
2024-06-03 14:32:19 ET Summary Alnylam Pharmaceuticals, Inc. is set to release clinical data from its HELIOS-B study in late June/early July, and this will have a significant impact on the company's share price. The success of the study could drive the share price to the high-$200...
2024-06-03 14:24:35 ET More on Pfizer, Takeda Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Turning The Corner (Rating Upgrade) Pfizer: Down To A Historically Low Valuation - Is It A Buy? Takeda gets positive opinion from EU regulat...
2024-06-03 14:14:05 ET Summary BridgeBio Pharma, Inc. stock has fallen by 10% since December, but recent trial data and analyst support have boosted investor enthusiasm recently. The company's primary drug candidate, Acoramidis, has a marketing application accepted by the FDA for ...
2024-06-03 13:03:00 ET Summary Corbus Pharmaceuticals Holdings, Inc. reported positive results achieved in phase 1 China study, using CRB-701 for patients with mUC and cervical cancer; 44% and 43% ORR achieved for each, respectively. The global urothelial carcinoma market is expec...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
2024-07-20 10:00:00 ET On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the mo...
2024-07-18 13:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...